Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302119 | PMC |
| http://dx.doi.org/10.25259/ijn_555_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic kidney disease (CKD) has shown a growing association with osteoporosis, comprising part of the broader CKD-mineral and bone disorder (CKD-MBD). CKD-MBD is marked by alterations in calcium, phosphorus, parathyroid hormone (PTH), and vitamin D metabolism, significantly elevating fracture risk. While traditional osteoporosis treatments such as bisphosphonates, denosumab, and teriparatide have been adapted for CKD patients, recent innovations have introduced agents aimed at enhancing bone mass and reducing fracture incidence.
View Article and Find Full Text PDFSurgical Management of Adult Spinal Deformity Patients with Osteoporosis.
J Clin Med
November 2024
Department of Orthopedic Surgery, The Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
Adult spinal deformity (ASD) commonly affects older adults, with up to 68% prevalence in those over 60, and is often complicated by osteoporosis, which reduces bone mineral density (BMD) and increases surgical risks. Osteoporotic patients undergoing ASD surgery face higher risks of complications like hardware failure, pseudoarthrosis, and proximal junctional kyphosis (PJK). Medical management with antiresorptive medications (e.
View Article and Find Full Text PDFVerifying the effectiveness of romosozumab re-administration on bone mineral density.
J Bone Miner Res
December 2024
Department of Orthopedic Surgery, Division of Osteoporosis, Locomotive Syndrome, Joint Disease Center, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan.
Upon completing romosozumab therapy for osteoporosis, sequential treatment with other agents is required. However, for patients at high fracture risk despite such therapy, re-administration of romosozumab might be a potent option for subsequent medication to prevent additional fractures. Currently, there is still insufficient real-world clinical data verifying the efficacy of romosozumab re-administration, therefore, this study aimed to evaluate its efficacy.
View Article and Find Full Text PDFManagement of multiple vertebral fractures during lactation in a patient with osteogenesis imperfecta type I following twin delivery.
JBMR Plus
January 2025
Department of Endocrinology, Monash Health, Clayton, Melbourne, Australia.
Osteogenesis imperfecta (OI) is an uncommon bone disorder caused by mutations in type I collagen involved in bone matrix leading to increased fracture risk. There are several sub-categories within OI, with OI type I being the most common and mildest form. Women with OI considering pregnancy need to be aware of bone loss and fracture risk, particularly with lactation.
View Article and Find Full Text PDFClinical Efficacy and Safety of Teriparatide Versus Alendronate in Postmenopausal Osteoporosis: A Systematic Review of Randomized Controlled Trials.
Cureus
November 2024
Pharmacology, Sir Seewoosagur Ramgoolam Medical College, Belle Rive, MUS.
Alendronate, a second-generation bisphosphonate, remains the first-line therapeutic option for postmenopausal osteoporosis. It acts on the bone resorbing osteoclasts causing their apoptosis. This is achieved by producing toxic adenosine triphosphate (ATP) analogues and interfering with the mevalonate pathway.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!